EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

CD20 CAR T cells safely and reversibly ablate B cell follicles in a non-human primate model of HIV persistence

John K Bui, Carly E Starke, Nikhita H Poole, Blake J Rust, Keith R Jerome, Hans-Peter Kiem, Christopher W Peterson

Molecular Therapy · 2024

DOI: 10.1016/j.ymthe.2024.02.030 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Therapy, 2024. Verfasst von John K Bui und 6 weiteren Autor:innen. Beteiligte Einrichtung: Stem Cell and Gene Therapy Program, Fred Hutchinson Cancer Center, Seattle, WA, USA; Department of Allergy and Infection Diseases, University of Wash…. Hauptthemen laut MEDLINE: Antigens, CD20, B-Lymphocytes, Disease Models, Animal, Simian Immunodeficiency Virus. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS, NHLBI NIH HHS, NIDDK NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor (CAR) T cell therapies have demonstrated immense clinical success for B cell and plasma cell malignancies. We tested their impact on the viral reservoir in a macaque model of HIV persistence, comparing the functions of CD20 CAR T cells between animals infected with simian/human immunodeficiency virus (SHIV) and uninfected controls. We focused on the potential of this approach to disrupt B cell follicles (BCFs), exposing infected cells for immune clearance. In SHIV-infected animals, CAR T cells were highly functional, with rapid expansion and trafficking to tissue-associated viral sanctuaries, including BCFs and gut-associated lymphoid tissue (GALT). CD20 CAR T cells potently ablated BCFs and depleted lymph-node-associated follicular helper T (TFH) cells, with complete restoration of BCF architecture and TFH cells following CAR T cell contraction. BCF ablation decreased the splenic SHIV reservoir but was insufficient for effective reductions in systemic viral reservoirs. Although associated with moderate hematologic toxicity, CD20 CAR T cells were well tolerated in SHIV-infected and control animals, supporting the feasibility of this therapy in people living with HIV with underlying B cell malignancies. Our findings highlight the unique ability of CD20 CAR T cells to safely and reversibly unmask TFH cells within BCF sanctuaries, informing future combinatorial HIV cure strategies designed to augment antiviral efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antigens, CD20B-LymphocytesDisease Models, AnimalSimian Immunodeficiency VirusImmunotherapy, AdoptiveSimian Acquired Immunodeficiency SyndromeHIV InfectionsReceptors, Chimeric AntigenAnimalsHumansT-LymphocytesHIV-1Viral LoadMacaca mulatta

Stichwörter der Autor:innen

B cell leukemiaCAR T cellCD20HIV-1immunotherapylymphoid folliclelymphomanon-human primate modelsolid tumor

Substanzen

Antigens, CD20Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Stem Cell and Gene Therapy Program, Fred Hutchinson Cancer Center, Seattle, WA, USA; Department of Allergy and Infection Diseases, University of Washington, Seattle, WA, USA.
  • Stem Cell and Gene Therapy Program, Fred Hutchinson Cancer Center, Seattle, WA, USA.
  • Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.
  • Stem Cell and Gene Therapy Program, Fred Hutchinson Cancer Center, Seattle, WA, USA; Department of Allergy and Infection Diseases, University of Washington, Seattle, WA, USA; Department of Medicine, University of Washin…
  • Stem Cell and Gene Therapy Program, Fred Hutchinson Cancer Center, Seattle, WA, USA; Department of Medicine, University of Washington, Seattle, WA, USA. Electronic address: cwpeters@fredhutch.org.

Förderung

  • NIAID NIH HHS
  • NHLBI NIH HHS
  • NIDDK NIH HHS
  • NIH HHS
  • NCI NIH HHS
  • University of Washington
  • Office of Research Infrastructure Programs
  • National Heart Lung and Blood Institute

Zitieren

APA

Bui, J. K., Starke, C. E., Poole, N. H., Rust, B. J., Jerome, K. R., Kiem, H. P., & Peterson, C. W. (2024). CD20 CAR T cells safely and reversibly ablate B cell follicles in a non-human primate model of HIV persistence. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2024.02.030

Vancouver

Bui JK, Starke CE, Poole NH, Rust BJ, Jerome KR, Kiem HP, et al. CD20 CAR T cells safely and reversibly ablate B cell follicles in a non-human primate model of HIV persistence. Molecular Therapy. 2024. doi:10.1016/j.ymthe.2024.02.030

BibTeX
@article{Bui2024,
  author = {Bui, John K and Starke, Carly E and Poole, Nikhita H and Rust, Blake J and Jerome, Keith R and Kiem, Hans-Peter and Peterson, Christopher W},
  title = {CD20 CAR T cells safely and reversibly ablate B cell follicles in a non-human primate model of HIV persistence},
  journal = {Molecular Therapy},
  year = {2024},
  doi = {10.1016/j.ymthe.2024.02.030}
}
Kostenlos starten →